antivrial
Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes
July 23, 2019Manufacturing and Production Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus
Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
